BioSpace News Archive

Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has approved EOHILIA the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE).

Sensome announced today enrollment of the first patients into a feasibility clinical study using the Clotild ® Smart Guidewire in peripheral artery disease (PAD).

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the opening of the 2024 Salix Gastrointestinal Health Scholars Program application period.

Through integration with Multiply Labs’ robotic technology, Thermo Fisher Scientific’s advanced, industry-leading cell therapy instruments, including the Thermo Scientific™ Heracell™ VIOS Automated Access CO 2 Incubator and the Gibco™ Cell Therapy Systems (CTS™) Rotea™ Counterflow Centrifugation System can now be fully automated for cell therapy manufacturing.

NovelMed today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Ruxoprubart, an alternative pathway (AP) blocker anti-Bb antibody, for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH).

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics.

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”) announced today that RJ Tesi, M.D., Chief Executive Officer, and David Moss, Chief Financial Officer, will present a corporate update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually from February 13-14, 2024.

As the use of robotic assistance in total knee arthroplasty has grown, there has been limited research looking at whether it improved the risk of revision.

Sentrex Health Solutions Inc., a leading provider of specialty healthcare services in Canada, is excited to announce the acquisition of PerCuro Clinical Research Ltd.—one of Canada’s premier providers of infusion services, clinical research, and advanced nursing care.

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal third quarter ended December 31, 2023.